The present disclosure provides a method for separating a neural crest derived cell from peripheral blood. In the present disclosure, a mononuclear cell is separated from the peripheral blood and then directly cultured, thereby maximizing use of a neural crest stem cell with a differentiation potential to avoid loss of the neural crest stem cell. In the method of the present disclosure, a sample to be separated is derived from the peripheral blood. The method shows less trauma and low cost. Most importantly, compared to extracting the neural crest derived cell from tissues, the neural crest derived cell extracted from the peripheral blood can be used clinically as a type of biomarker.

Provided herein are methods of reducing or eliminating undifferentiated pluripotent stem cells, where the methods comprise contacting an effective amount of a compound to a heterogeneous cell population or sample comprising or suspected of comprising differentiated cell types and undifferentiated pluripotent stem cells, whereby the contacting selectively reduces or eliminates undifferentiated pluripotent stem cells from the cell population or sample. Also provided are methods for obtaining a population of stem cell-derived cell types substantially free of undifferentiated pluripotent stem cells as well as isolated populations of such of stem cell-derived cell types.

This invention establishes a new paradigm for treatment of Parkinson's disease (PD) by eliminating senescent cells that reside in or around the site of the disease pathophysiology. Exposure of test subjects to the herbicide paraquat (PQ) increases the risk for developing Parkinson's disease. The data in this disclosure show that PQ induces a senescence arrest and SASP in astrocytes, in culture and in vivo in mice, and senescent cell markers were present in astrocytes in midbrain tissue from PD patients. In a transgenic mouse model, senescent cell ablation protected against PQ-induced PD-like neuropathology. Removal of senescent cells from affected sites using small molecule agents that specifically target senescent cells can help prevent or ameliorate signs and symptoms of the disease.

An alternating vacuum and pressure system for decellularizing a bone matrix includes piping having a first end open to atmospheric pressure and a second end open to atmospheric pressure, and a subset of piping that forms a loop, a chamber in fluid, at least one heating element configured to heat the piping, a pump, and a plurality of valves. The plurality of valves can be selectively opened or closed to form one of a plurality of configurations, including a pressure configuration in which operation of the pump in a first direction causes a fluid within the piping to travel toward the chamber such that pressure is applied to the chamber and a vacuum configuration in which operation of the pump in a second direction causes the fluid within the pipe to travel away from the chamber such that a vacuum is created on the chamber.

Provided is a cell culture apparatus including a culture vessel that stores a cell suspension containing cells; a first filter part that has a first filter membrane that performs membrane separation treatment on the cell suspension extracted from the culture vessel; a first circulation flow path that allows components blocked by the first filter membrane to return to the culture vessel; a second filter part that has a second filter membrane that performs membrane separation treatment on components of the cell suspension permeated through the first filter membrane; a second circulation flow path that allows components permeated through the second filter membrane to return to the culture vessel; and a recovery flow path that recovers components blocked by the second filter membrane. In the cell culture apparatus, an average hole diameter of the first filter membrane is 20 m or smaller, and 0<B/A0.5 is satisfied in a case where an average hole diameter of the first filter membrane is A and an average hole diameter of the second filter membrane is B; or an average hole diameter of the first filter membrane is 20 m or smaller, and the second filter membrane is an ultrafiltration membrane.

Provided herein are methods of reducing or eliminating undifferentiated pluripotent stem cells, where the methods comprise contacting an effective amount of a compound to a heterogeneous cell population or sample comprising or suspected of comprising differentiated cell types and undifferentiated pluripotent stem cells, whereby the contacting selectively reduces or eliminates undifferentiated pluripotent stem cells from the cell population or sample. Also provided are methods for obtaining a population of stem cell-derived cell types substantially free of undifferentiated pluripotent stem cells as well as isolated populations of such of stem cell-derived cell types.

An antibody that binds a glycosylated protein is disclosed, wherein the glycosylation comprises the glycan motif Fuc1-2Gal1-3GlcNAc1-3Gal1 or Fuc1-2Gal1-3GlcNAc. Antibodies that are cytotoxic against undifferentiated pluripotent cells are also disclosed.

The present teachings provide for methods of separating live and dead spermatozoa cells from non-human mammalian sex-selected semen. Sex-selected semen is first treated with proteinase K and TCEP, then applied to a density gradient media for separation. Separation is typically accomplished through centrifugation. Commercially available density gradient media include PERCOLL? and BOVIPURE?. Separation of live and dead cells in sex selected semen allows for precise quantification of sex skew using ddPCR?.

The present invention relates to a method for the diagnosis of tumoural conditions and/or of the corresponding state of advance, wherein a sample from a patient comprising at least one tumour cell is obtained. According to the invention, a purified specimen of the at least one tumour cell is obtained by individually selecting and isolating single cells in a microfluidic device the purified specimen having a purity of at least 90%. On the purified specimen thus obtained there is subsequently performed a molecular analysis such as to highlight a characteristic thereof suited to enabling diagnosis.

This invention establishes a new paradigm for treatment of Parkinson's disease (PD) by eliminating senescent cells that reside in or around the site of the disease pathophysiology. Exposure of test subjects to the herbicide paraquat (PQ) increases the risk for developing Parkinson's disease. The data in this disclosure show that PQ induces a senescence arrest and SASP in astrocytes, in culture and in vivo in mice, and senescent cell markers were present in astrocytes in midbrain tissue from PD patients. In a transgenic mouse model, senescent cell ablation protected against PQ-induced PD-like neuropathology. Removal of senescent cells from affected sites using small molecule agents that specifically target senescent cells can help prevent or ameliorate signs and symptoms of the disease.